Event
Vitestro raises $70M Series B to advance autonomous robotic phlebotomy and commercial readiness
Key points
- Vitestro raised an oversubscribed $70M Series B to support the next generation of Aletta and broader commercial readiness.
- Proceeds will support U.S. FDA De Novo work, manufacturing scale-up, clinical expansion, and commercial infrastructure development.
- The round included strategic healthcare backers including Labcorp Venture Fund, Mayo Clinic, and Sutter Health alongside existing investors.
Company context
Develops autonomous robotic blood collection systems for clinical settings. Its Aletta platform is an autonomous robotic phlebotomy device that uses multimodal imaging, robotics, and AI to identify veins, insert the needle, collect diagnostic blood tubes, and complete the venous blood draw workflow. The company is focused on hospital and outpatient diagnostic workflows, with CE-marked deployment in Europe and U.S. regulatory work underway.
Context
- Company
- Vitestro
- Segment
- Healthcare
- Event type
- Funding
- Geography
- Utrecht · Netherlands